Overview

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Status:
Active, not recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).

Phase:

Phase 3

Details

Lead Sponsor:

Alnylam Pharmaceuticals